Hollencrest Capital Management’s ProShares Ultra CRCL CRCA Stock Holding History

Hollencrest Capital Management’s Portfolio CRCA Stock Details CRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,280	Closed	-$133K	–	1330
2025 Q4	$133K	Buy	+3,280	New	+$281K	﹤0.01%	403

Other funds holding CRCA

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Hollencrest Capital Management's CRCA Position: Q1 2026 in Review

Hollencrest Capital Management sold out of ProShares Ultra CRCL (CRCA) in Q1 2026, closing a stake of 3,280 shares — an estimated $133K sold.

Hollencrest Capital Management first reported a position in CRCA in Q4 2025 and held it in 1 quarter. The position peaked at $133K in Q4 2025. 7 funds tracked by Wall St. Rank hold CRCA as of Q1 2026.

Hollencrest Capital Management reported no remaining ProShares Ultra CRCL position as of Q1 2026 after selling out during the quarter.
Hollencrest Capital Management sold 3,280 ProShares Ultra CRCL shares in Q1 2026, an estimated $133K.
Hollencrest Capital Management first reported a position in ProShares Ultra CRCL in Q4 2025 and held it in 1 quarter.
Hollencrest Capital Management's ProShares Ultra CRCL position peaked at $133K in Q4 2025.
7 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q1 2026.

Based on Hollencrest Capital Management's 13F filing for Q1 2026, filed 7 May 2026.